Evidence map›Paper›PMID 40281056›Full record

ArticleNPJ precision oncology2025

A promptable CT foundation model for solid tumor evaluation.

Léo Machado, Léo Alberge, Hélène Philippe, Elodie Ferreres, Julien Khlaut, Julie Dupuis, Korentin Le Floch, Denis Habip Gatenyo, Pascal Roux, Jules Grégory and 6 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. A Promptable 3D-CT Foundation Model-Based Approach for Pulmonary Embolism.Cardiovascular and interventional radiology · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Léo MachadoRaidium, Paris Biotech Santé, Paris, France.
Léo AlbergeRaidium, Paris Biotech Santé, Paris, France.
Hélène PhilippeRaidium, Paris Biotech Santé, Paris, France.
Elodie FerreresRaidium, Paris Biotech Santé, Paris, France.
Julien KhlautRaidium, Paris Biotech Santé, Paris, France.
Julie DupuisRaidium, Paris Biotech Santé, Paris, France.
Korentin Le FlochRaidium, Paris Biotech Santé, Paris, France.
Denis Habip GatenyoDepartment of Radiology, Hôpital Cochin, AP-HP, Paris, France.
Pascal RouxCentre d'Imagerie du Nord, Saint-Denis, France.
Jules GrégoryAP-HP. Nord, Department of Radiology, FHU MOSAIC, Beaujon Hospital, Clichy, France.
Maxime RonotAP-HP. Nord, Department of Radiology, FHU MOSAIC, Beaujon Hospital, Clichy, France. maxime.ronot@aphp.fr.
Corentin DancetteRaidium, Paris Biotech Santé, Paris, France.
Tom BoekenDepartment of Vascular and Oncological Interventional Radiology, Université Paris Cité, AP-HP, Hôpital Européen Georges Pompidou, HEKA INRIA, Paris, France.
Daniel TordjmanRaidium, Paris Biotech Santé, Paris, France.
Pierre ManceronRaidium, Paris Biotech Santé, Paris, France.
Paul HérentRaidium, Paris Biotech Santé, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinogenesis is inherently complex, resulting in heterogeneous tumors with variable outcomes and frequent metastatic potential. Conventional longitudinal evaluation methods like RECIST 1.1 remain labor-intensive and prone to measurement errors, while existing AI solutions face critical limitations due to tumor heterogeneity, insufficient annotations, and lack of user interaction. We developed ONCOPILOT, an interactive CT-based foundation model dedicated to 3D tumor segmentation, significantly refining RECIST 1.1 evaluations with active radiologist engagement. Trained on more than 8000 CT scans, ONCOPILOT employs intuitive visual prompts, including point-click, bounding boxes, and edit-points. It attains segmentation accuracy that matches or exceeds state-of-the-art methods, provides radiologist-level precision for RECIST 1.1 measurements, reduces inter-observer variability, and enhances workflow efficiency. Integrating clinical expertise with interactive AI capabilities, ONCOPILOT facilitates widespread access to advanced biomarkers, notably volumetric tumor analyses, thereby supporting improved clinical decision-making, patient stratification, and accelerating advancements in oncology research.

Identifiers

PMID40281056
PMCPMC12032241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.